Cardiac allograft vasculopathy: Do adipocytes bridge alloimmune and metabolic risk factors?

Current Opinion in Organ Transplantation

Volumn 15, Issue 5, 2010, Pages 639-644

  Wehner, Jennifer R ^a   Baldwin, William M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

adiponectin; antibody mediated rejection; perivascular adipose tissue; proinflammatory cytokines; vasculopathy

Indexed keywords

ADIPONECTIN; ALLOANTIBODY; AUTOANTIBODY; CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; ALLOIMMUNITY; CARDIAC ALLOGRAFT VASCULOPATHY; CORONARY ARTERY; DISEASE ASSOCIATION; HUMAN; INTIMA; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; VASCULAR ENDOTHELIUM;

ADIPOCYTES; ADIPOKINES; ANIMALS; AUTOANTIBODIES; CHRONIC DISEASE; CORONARY ARTERY DISEASE; CYTOKINES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; INFLAMMATION MEDIATORS; ISOANTIBODIES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77957579885     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32833deaee     Document Type: Review

References (32)

1. Taylor DO, Stehlik J, Edwards L.B., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-sixth Official Adult Heart Transplant Report-2009. J Heart Lung Transplant 2009; 28: 1007-1022.
2. Wu GW, Kobashigawa JA, Fishbein M.C., et al. Asymptomatic antibody- mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant 2009; 28: 417-422.
3. Kfoury AG, Hammond ME Controversies in defining cardiac antibody- mediated rejection: need for updated criteria. J Heart Lung Transplant 2010; 29: 389-394.
4. Kucirka LM, Maleszewski JJ, Segev D.L., Halushka MK Survey of North American pathologist practices regarding antibody-mediated rejection in cardiac transplant biopsies. Cardiovasc Pathol 2010 [Epub ahead of print].
5. Rodriguez ER, Skojec DV, Tan C.D., et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant 2005; 5: 2778-2785.
6. Tan CD, Sokos GG, Pidwell DJ, et al. Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection. Am J Transplant 2009; 9: 2075-2084.
7. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant 2009; 9: 1826-1834.
8. Loupy A, Suberbielle-Boissel C, Hill G.S., et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570.
9. Sis B, Jhangri GS, Bunnag S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312-2323.
10. Sis B, Halloran PF Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transpl 2010; 15: 42-48.
11. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria: an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
12. Crespo-Leiro M.G., Veiga-Barreiro A, Domenech N., et al. Humoral heart rejection (severe allograft dysfunction with no signs of cellular rejection or ischemia): incidence, management, and the value of C4d for diagnosis. Am J Transplant 2005; 5: 2560-2564.
13. Smith JD, Brunner VM, Jigjidsuren S, et al. Lack of effect of MICA antibodies on graft survival following heart transplantation. Am J Transplant 2009; 9: 1912-1919.
14. Tan JC, Wadia PP, Coram M, et al. H-Y antibody development associates with acute rejection in female patients with male kidney transplants. Transplantation 2008; 86: 75-81.
15. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71: 886-892.
16. Leong HS, Mahesh BM, Day J.R., et al. Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor. J Leukoc Biol 2008; 83: 263-271.
17. Kirk AD, Morrell CN, Baldwin WM 3rd. Platelets influence vascularized organ transplants from start to finish. Am J Transplant 2009; 9: 14-22.
18. Morrell CN, Sun H, Swaim A.M., Baldwin WM III. Platelets, an inflammatory force in transplantation. Am J Transplant 2007; 7: 2447-2454.
19. Morrell CN, Murata K, Swaim A.M., et al. In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ Res 2008; 102: 777-785.
20. Russell PS, Chase CM, Winn H.J., Colvin RB Coronary atherosclerosis in transplanted mouse hearts II. Importance of humoral immunity. J Immunol 1994; 152: 5135-5141.
21. Uehara S, Chase C, Cornell L, et al. Chronic cardiac transplant arteriopathy in mice: relationship of alloantibody, C4d deposition and neointimal fibrosis. Am J Transpl 2007; 7: 57-65.
22. Hirohashi T, Uehara S, Chase C.M., et al. Complement independent antibody- mediated endarteritis and transplant arteriopathy in mice. Am J Transplant 2010; 10: 510-517.
23. Galvani S, Auge N, Calise D., et al. HLA class I antibodies provoke graft arteriosclerosis in human arteries transplanted into SCID/beige mice. Am J Transplant 2009; 9: 2607-2614.
24. Kelishadi SS, Azimzadeh AM, Zhang T, et al. Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys. J Clin Invest 2010; 120: 1275-1284.
25. Hagemeijer MC, van Oosterhout MF, van Wichen DF, et al. T cells in cardiac allograft vasculopathy are skewed to memory Th-1 cells in the presence of a distinct Th-2 population. Am J Transplant 2008; 8: 1040-1050.
26. Wehner JR, Fox-Talbot K, Halushka M.K., et al. B cells and plasma cells in coronaries of chronically rejected cardiac transplants. Transplantation 2010; 89: 1141-1148.
27. Chatterjee TK, Stoll LL, Denning G.M., et al. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res 2009; 104: 541-549.
28. Ohashi K, Parker JL, Ouchi N, et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 2010; 285: 6153-6160.
29. Ouedraogo R, Gong Y, Berzins B., et al. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 2007; 117: 1718-1726.
30. Okamoto Y, Christen T, Shimizu K., et al. Adiponectin inhibits allograft rejection in murine cardiac transplantation. Transplantation 2009; 88: 879-883. Demonstrates that systemic adiponectin modulates acute allograft rejection.
31. Takaoka M, Nagata D, Kihara S., et al. Periadventitial adipose tissue plays a critical role in vascular remodeling. Circ Res 2009; 105: 906-911.
32. Alexaki VI, Notas G, Pelekanou V., et al. Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn1 4, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development. J Immunol 2009; 183: 5948-5956.